Pharm
Trimethoprim Sulfamethoxazole
search
Trimethoprim Sulfamethoxazole
, SMX-TMP, TMP-SMZ, Bactrim, Sulfatrim, Co-trimoxazole, Septra
See Also
Sulfonamide
Sulfonamide Allergy
Indications
Organisms
Enteric
Gram Negative Bacteria
(esp.
Urinary Tract Infection
s)
Conditions
Urinary Tract Infection
Pneumocystis carinii
prophylaxis and treatment
MRSA
Skin Infection
s
Contraindications
Avoid in infant under age 2 months (
Kernicterus
risk)
Sulfonamide Allergy
G6PD Deficiency
Avoid in
Streptococcal Pharyngitis
,
Acute Otitis Media
and
Acute Sinusitis
(high
Antibiotic Resistance
rates)
Stage 5
Chronic Kidney Disease
(eGFR <15 ml/min)
Mechanism
See
Sulfonamide
Precautions
Prolonged use may cause very severe adverse reactions
Follow
Complete Blood Count
(CBC) in prolonged use
Hyperkalemia
risk (especially in
Renal Insufficiency
, related to trimethoprim component)
Medications
Double Strength (DS)
Trimethoprim 160 mg
Sulfamethoxazole 800 mg
Single Strength (SS)
Trimethoprim 80 mg
Sulfamethoxazole 400 mg
Pediatric Suspension (40/200 per 5 ml)
Trimethoprim 40 mg per 5 ml
Sulfamethoxazole 200 mg per 5 ml
Dosing
Directions (regarding
Sulfonamide
component)
Take on an empty
Stomach
Take more than 1 hour before or two hours after food
Dosing
Adult (or child weight >40 kg)
See
Pneumocystis Prophylaxis
See
PCP Pneumonia
Standard Dosing (e.g.
Urinary Tract Infection
)
Take 1 DS tablet (160/800 mg) orally twice daily
Higher Dosing (e.g. MRSA
Cellulitis
)
Take 1-2 DS tablet orally twice daily
Dosing
Child (weight <40 kg)
Avoid in age <2 months old (
Kernicterus
risk),
G6PD
or marked
Hyperbilirubinemia
(see above)
Dosing uses 40/200 mg per 5 ml suspension
Treatment (e.g.
Urinary Tract Infection
)
Dose 1 ml/kg/day divided twice daily orally (40/200 per 5 ml suspension)
Alternatively dose 8 mg/kg/day of TMP component orally divided twice daily
Doses up to 1.5 ml/kg/day may be used in MRSA
Skin Infection
s (see
Cellulitis
)
Maximum: 20 ml (160/800 mg) orally twice daily
For each 10 kg weight, dose 5 ml suspension twice daily (up to maximum of 20 ml/dose)
Age 2 months (5 kg): 2.5 ml orally twice daily
Age 1 year (10 kg): 5.0 ml orally twice daily
Age 3 years (15 kg): 7.5 ml orally twice daily
Age 5 years (20 kg): 10 ml orally twice daily
Prophylaxis of
Urinary Tract Infection
s
Dose: 4 mg/kg/day of Trimethoprim dosed once daily
Dosing
Renal (eGFR <30 ml/min)
eGFR 15 to 30 ml/min (Stage 4
Chronic Kidney Disease
)
Decrease Trimethoprim-Sulfamethoxazole dose by 50%
eGFR <15 ml/min (Stage 5
Chronic Kidney Disease
)
Avoid the use of Trimethoprim Sulfamethoxazole
Dosing
HIV
Pneumocystis Treatment
Take 15 to 20 mg/kg/day of TMP component orally or IV divided every 8 hours for 21 days
Adult with mild to moderate infections
Take 2 DS tablets orally three times daily for 21 days
Child
Take 5 ml suspension (40/200 mg) per every 8 kg orally every 6 hours for 21 days
Pneumocystis Prophylaxis
Adult
Take one tablet DS orally daily (per FDA labeling) OR
Take one tablet SS orally daily (off label use)
Child
Take 150 mg/m2/day of TMP component orally divided twice daily on 3 consecutive days per week
Adverse Effects
Gene
ral
See
Sulfonamide
Allergic Reaction
or
Anaphylaxis
See
Sulfonamide Allergy
Bone Marrow
suppression (
Agranulocytosis
)
Highest risk with prolonged use, or high dose IV use
Steven's Johnson Syndrome
Toxic Epidermal Necrolysis
Hyperkalemia
Related to trimethoprim component
Higher risk with underlying
Renal Insufficiency
Exacerbated by
ACE Inhibitor
,
Angiotensin Receptor Blocker
, and
Potassium
supplements
Neonatal Hyperbilirubinemia
and
Kernicterus
Sulfonamide
s compete with
Bilirubin
for albumin binding
Results in increased free
Bilirubin
, with risk of
Neonatal Hyperbilirubinemia
and
Kernicterus
Propylene glycol toxicity
Associated with high dose IV use (e.g.
PCP Pneumonia
)
Adverse Effects
HIV patients (40-60% within 3 weeks)
Hepatitis
Neutropenia
Anemia
Hyponatremia
Hyperkalemia
(6% of patients, esp. elderly)
Nausea
or
Vomiting
Rash
Fever
Safety
Pregnancy
Avoid in first and third trimesters (considered safe in second trimester)
Lactation
Avoid in first month of life (
Hyperbilirubinemia
Kernicterus
risk)
Avoid in maternal or infant
G6PD Deficiency
Otherwise considered safe in
Lactation
after first month of life
Drug Interactions
Other drugs decrease Trimethoprim Sulfamethoxazole levels
Rifampin
Trimethoprim Sulfamethoxazole increases other drug levels
Phenytoin
(
Dilantin
)
Methotrexate
Warfarin
Trimethoprim Sulfamethoxazole increases
Warfarin
effects and may result in up to a 3 fold increase in INR
Monitor INR and plan 25-50%
Warfarin
dose reduction while on Trimethoprim Sulfamethoxazole
Hyperkalemia
risk
Increased risk with
ACE Inhibitor
s,
Angiotensin Receptor Blocker
s,
Spironolactone
Higher risk with age >65 years,
Renal Insufficiency
,
Diabetes Mellitus
and
Heart Failure
Significantly increased rate of hospitalization and sudden death
Avoid Septra use for longer than three days with these agents and comorbidities in age >65 years
Consider alternative
Antibiotic
s, holding
Antihypertensive
or recheck
Serum Potassium
in 4-5 days
Fralick (2014) BMJ 349:g6196 +PMID:25359996 [PubMed]
References
(2014) Presc lett 21(8): 47
Resources
Trimethoprim Sulfamethoxazole Tablet (DailyMed)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f59d0c04-9c66-4d53-a0e1-cb55570deb62
Trimethoprim Sulfamethoxazole Suspension (DailyMed)
https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a6182855-6287-45e9-b6b4-7b57efc9c76e
Trimethoprim Sulfamethoxazole Injection Solution (DailyMed)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b89b5502-ce87-45a6-a43c-9891da3cfca4
References
Hamilton (2020) Tarascon Pocket Pharmacopoeia
Kemnic (2023) Trimethoprim Sulfamethoxazole, StatPearls, Treasure Island, Florida
https://www.ncbi.nlm.nih.gov/books/NBK513232/
Type your search phrase here